Details of the Drug Combination

General Information of Drug Combination (ID: DCOHHP3)

Drug Combination Name
Carboplatin TAS-106
Indication
Disease Entry Status REF
Cancer Phase 1 [1]
Component Drugs Carboplatin   DMG281S TAS-106   DML97KB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Carboplatin
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [2]
Carcinoma 2A00-2F9Z Approved [2]
Cholangiocarcinoma 2C12.10 Approved [2]
Cutaneous melanoma 2C30 Approved [2]
Epithelial ovarian cancer 2B5D Approved [2]
Fallopian tube neoplasm N.A. Approved [2]
Gastroesophageal junction adenocarcinoma 2B71 Approved [2]
Lung adenocarcinoma N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Ovarian cancer 2C73 Approved [3]
Ovarian disorder N.A. Approved [2]
Ovarian neoplasm N.A. Approved [2]
Ovarian serous cystadenocarcinoma N.A. Approved [2]
Small-cell lung cancer 2C25.Y Approved [2]
Lung large cell carcinoma N.A. Investigative [2]
Neuroblastoma 2D11.2 Investigative [2]
Carboplatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Carboplatin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Carboplatin Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Metabolism [7]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Metabolism [7]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Metabolism [7]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Metabolism [7]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Metabolism [7]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Metabolism [7]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)
Indication(s) of TAS-106
Disease Entry ICD 11 Status REF
Head and neck cancer 2D42 Phase 2 [4]
TAS-106 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium RNA polymerase (MycB RNAP) TT79JGK RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU Modulator [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00752011) Phase I Study of TAS-106 in Combo With Carboplatin
2 Carboplatin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
4 ClinicalTrials.gov (NCT00737360) Phase II Study of TAS-106 to Treat Head and Neck Cancer. U.S. National Institutes of Health.
5 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
6 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
7 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
8 Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26.